This paper is in the following e-collection/theme issue:

Cancer Epidemiology, Cancer Surveillance and Infodemiology (78) Medicine 2.0: Social Media, Open, Participatory, Collaborative Medicine (1666) Infodemiology and Infoveillance (1369) Skin Cancer and Melanoma Prevention (113) Mass Media/Social Media Communication and Campaigns (466) Infoveillance, Infodemiology, Digital Disease Surveillance, Infodemic Management (1050)

Published on in Vol 8, No 2 (2022): Apr-Jun

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/35930, first published .
Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis

Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis

Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis

Authors of this article:

Jyoti Chauhan1 Author Orcid Image ;   Sathyaraj Aasaithambi1 Author Orcid Image ;   Iván Márquez-Rodas2, 3 Author Orcid Image ;   Luigi Formisano4 Author Orcid Image ;   Sophie Papa5 Author Orcid Image ;   Nicolas Meyer6, 7 Author Orcid Image ;   Andrea Forschner8 Author Orcid Image ;   Guy Faust9 Author Orcid Image ;   Mike Lau10 Author Orcid Image ;   Alexandros Sagkriotis10 Author Orcid Image
Article Authors Cited by (6) Tweetations (6) Metrics

Jyoti Chauhan   1 , MBA ;   Sathyaraj Aasaithambi   1 , MSc ;   Iván Márquez-Rodas   2, 3 , MD, PhD ;   Luigi Formisano   4 , MD, PhD ;   Sophie Papa   5 , MD, PhD ;   Nicolas Meyer   6, 7 , MD, PhD ;   Andrea Forschner   8 , MD ;   Guy Faust   9 , MD ;   Mike Lau   10 , PhD ;   Alexandros Sagkriotis   10 , MSc

1 Novartis Healthcare Pvt Ltd, Hyderabad, India

2 Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

3 Centro de Investigación Biomédica en Red Cáncer, Universidad Complutense, Madrid, Spain

4 Department of Clinical Medicine and Surgery, University of Naples “Federico II”, Naples, Italy

5 School of Cancer and Pharmaceutical Studies, King's College London, London, United Kingdom

6 Department of Onco-Dermatology, Toulouse Cancer Institute, Toulouse, France

7 Oncology Department, Toulouse University Hospital, Toulouse, France

8 Department of Dermatology, University Hospital Tübingen, Tübingen, Germany

9 Department of Oncology, University Hospitals of Leicester, Leicester, United Kingdom

10 Novartis Pharma AG, Basel, Switzerland

Corresponding Author: